MedTrace Logo

Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

NCT05911724 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-01-07

No results posted yet for this study

Summary

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

Conditions

Interventions

OTHER

Group I Healthy

Healthy Subjects

DRUG

CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group II: Stable Angina Patients

DRUG

HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group III: Heart Failure Patients

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Ibtsam Khairat, Ass. Prof. · Tanta University

  • Ahmed A. El-Sherbeni, Lecturer · Tanta University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-09-20
Completion
2024-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05911724 on ClinicalTrials.gov